Skip to main content
Updated June 1, 2026 — Comment period closes June 29 (28 days left)

FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide from the 503B Bulks List

On May 1, 2026, the FDA published a proposed rule declining to add the three leading GLP-1 receptor agonists to the 503B bulks list. If finalized, outsourcing facilities lose the legal pathway to compound these drugs at scale from bulk active ingredient. The comment period closes June 29, 2026.

June 1, 2026 Status Update: 28 Days Until Comment Close

The Federal Register comment docket has accumulated comments from compounding pharmacy trade groups, telehealth platforms, and patient advocacy organizations through May. The FDA has not extended the deadline, and no signal of softening has emerged in the agency's public statements. Expect a final rule within 3-6 months of the June 29 close, consistent with the FDA's timeline on prior 503B bulks list determinations.

What changed between May 29 and June 1: the Outsourcing Facilities Association filed its formal comment opposing the exclusion, citing supply continuity concerns. Eli Lilly and Novo Nordisk submitted comments supporting the exclusion. Several state pharmacy boards have begun issuing guidance to 503A pharmacies about transition expectations if the rule finalizes.

Compounded GLP-1 patients currently sourcing through telehealth platforms should expect supply interruptions starting Q3-Q4 2026 if the rule moves to a final order. For background on the parallel research peptide market — including retatrutide availability as a non-503B-affected peptide — see our related coverage.

What the FDA proposed

On May 1, 2026, the Food and Drug Administration published a notice in the Federal Register titled "List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act." The notice formally declines to add semaglutide, tirzepatide, and liraglutide to the 503B bulks list. The agency reviewed the nominations submitted by outsourcing facilities and concluded the evidence does not establish a clinical need for compounding these substances from bulk active pharmaceutical ingredient.

The notice opened a 60-day public comment period. Electronic and written comments must be submitted by June 29, 2026. The FDA will review comments before issuing a final rule. The proposed exclusion is the most significant federal action against compounded GLP-1 supply since the agency declared the semaglutide and tirzepatide shortages resolved in 2024 and 2025.

Why this matters for compounded GLP-1 supply

When the semaglutide shortage was active from 2023 through October 2024, and the tirzepatide shortage from 2023 through February 2025, 503B outsourcing facilities had a clear legal pathway: compound the drug from bulk active ingredient under the shortage exception in section 503B. That pathway closed when the FDA delisted the shortages. The bulks list was the alternative legal route: if the FDA had added semaglutide, tirzepatide, and liraglutide to the 503B bulks list, outsourcing facilities could have continued large-scale compounding even after the shortages ended.

The May 1 proposed rule shuts that alternative route. If finalized, 503B outsourcing facilities cannot compound the three drugs from bulk substance regardless of patient need or supply conditions. Some compounding can continue through 503A pharmacies for individual patient prescriptions with documented clinical need, but the high-volume telehealth model that depended on 503B outsourcing facilities does not survive in its current form. See our guide on compounded semaglutide legal status for the broader regulatory picture.

PathwayActive during shortageActive after shortageIf May 1 rule finalizes
503B outsourcing under shortage exceptionOpenClosedClosed
503B outsourcing under bulks listPending FDA decisionPending FDA decisionClosed
503A patient-specific compoundingOpenNarrowNarrow, with clinical-need scrutiny

The FDA definition of clinical need

The bulks list framework turns on a single statutory phrase: clinical need. The FDA has interpreted this term consistently for years. Clinical need means a documented medical reason the FDA-approved version of a drug cannot meet a patient need. Examples that count: an excipient allergy that requires a custom formulation, a strength not commercially available that is appropriate for a specific patient, or a dosage form (such as a topical or a different injection site) that the approved product does not offer.

Examples that do not count under the agency interpretation: cost, insurance coverage gaps, patient preference for compounded over branded, marketing differentiation by telehealth providers, and convenience. The compounding industry has argued for years that high cost is itself a clinical access barrier that should qualify as clinical need. The FDA has rejected this framing in every public statement and rule on the topic. The May 1 proposed rule reaffirms the position.

Why patients are searching "is compounded GLP-1 still legal"

For the last two years, the dominant search query around compounded GLP-1s has been "buy compounded semaglutide cheap." That intent is shifting in real time. Search volume for "is compounded semaglutide still legal" and "FDA compounded GLP-1 ban" spiked in May 2026 after the proposed rule landed. Patients on compounded therapy at $200-300 per month want to know whether their supply will continue and whether their telehealth provider has a path to keep dispensing.

The honest answer is that the May 1 proposed rule is the second-to-last step in a sequence that started in 2024. Step one was declaring the shortages resolved. Step two is excluding from the bulks list. Step three is enforcement action against 503A pharmacies that continue compounding under thin clinical-need rationales. Patients on compounded GLP-1s should expect their supply to narrow over the next 12 months and should plan accordingly.

Alternatives for patients losing compounded access

The path of least resistance for most patients losing compounded access is the manufacturer direct-to-consumer programs.

  • Wegovy through Novo Nordisk's NovoCare Pharmacy ships at a flat cash price for self-pay patients. See our Wegovy cost guide for current pricing.
  • Zepbound through Lilly Direct vials offers a lower-priced single-dose vial format. See our Zepbound cost guide.
  • Rybelsus, the oral semaglutide tablet, is sometimes available with lower out-of-pocket cost depending on insurance.
  • Insurance appeal if your plan covers GLP-1s for obesity or type 2 diabetes and is denying coverage. Document weight history, comorbidities, and prior weight management attempts.

Switching to a research-grade or international supply is not a safe alternative. Quality, identity, and purity are unverified, and importing prescription drugs from outside the US is illegal under federal law. See our broader guide on buying peptides online safely for the framework we apply to vendor evaluation.

How to submit a comment

The comment period closes June 29, 2026. The most effective comments address the FDA criteria directly rather than expressing general opposition.

  1. Go to regulations.gov and search for the Federal Register notice number 2026-08552 or docket number FDA-2026-N.
  2. Click the "Comment" button on the docket page.
  3. Submit your comment through the web form or upload a PDF.
  4. Frame your comment around the FDA criteria for clinical need. Specific clinical examples carry more weight than cost arguments, which the FDA has already rejected.
  5. The docket is public. Anything you submit becomes part of the rulemaking record.

Timeline from here

The likely sequence over the next 18 months:

  • June 29, 2026: Comment period closes.
  • Q3 2026: FDA reviews comments. Industry, telehealth, and patient advocacy submissions argue for revisions.
  • Q4 2026 to Q1 2027: FDA issues final rule. Based on the agency's consistent position, finalization without major changes is the base case.
  • 2027: 503B outsourcing facilities lose legal pathway. Compounded GLP-1 supply through this channel ends. 503A pharmacies face increasing enforcement scrutiny.
  • Through 2027: Branded prices may adjust downward to capture patients formerly on compounded therapy. Lilly and Novo Nordisk direct-to-consumer programs likely expand.

Bottom line

The May 1 proposed rule is not a surprise to anyone tracking the regulatory arc. It is the inevitable next step after the shortages were declared resolved. For patients on compounded semaglutide or tirzepatide, the next 12 months are the window to map a transition to branded therapy or to a different intervention. For telehealth providers built on compounded GLP-1s, the business model needs to evolve toward branded distribution or different drug classes. The clinical-need framework, applied consistently, leaves cost-driven access to advocacy and legislative channels, not to compounding.

Sources

Frequently Asked Questions About Compounded GLP-1s

The FDA published a proposed rule in the Federal Register declining to add semaglutide, tirzepatide, or liraglutide to the 503B bulks list. The agency reviewed the nominations submitted by outsourcing facilities and concluded there is no clinical need for compounding these three drugs from bulk active pharmaceutical ingredient. If finalized, 503B outsourcing facilities lose the legal route to large-scale GLP-1 compounding.

Electronic and written comments must be submitted by June 29, 2026 through the regulations.gov docket. Docket number FDA-2026-N for the proposed rule. After the comment period closes, the FDA reviews input and issues a final rule, which can take several months to a year.

For now, yes, but the legal basis is narrower than it was. The FDA declared the semaglutide and tirzepatide shortages resolved in October 2024 and February 2025 respectively. Once a drug is off the shortage list, 503B outsourcing facilities cannot compound it from bulk substance under the shortage exception. 503A pharmacies retain limited compounding rights when a prescription is patient-specific and there is a documented clinical reason the FDA-approved product does not work. The May 1 proposed rule, if finalized, removes the bulks list as a separate legal pathway for outsourcing facilities.

Section 503A covers traditional pharmacy compounding for an individual patient pursuant to a valid prescription. 503A pharmacies can only compound at smaller scale, must have a patient-specific prescription, and have limited bulk drug substance use. Section 503B covers outsourcing facilities that compound at larger scale, can ship without patient-specific prescriptions, and must register with the FDA. The 503B bulks list governs which bulk substances 503B outsourcing facilities may use. The May 1 proposal targets 503B only, but in practice 503B is the supply chain that fed most telehealth GLP-1 compounding.

The FDA narrowly defines clinical need as a documented medical reason the FDA-approved version of a drug cannot meet patient needs. Cost is not a clinical need under the agency interpretation. Patient preference is not a clinical need. Insurance coverage gaps are not a clinical need. What counts is a specific medical contraindication or formulation requirement, such as an allergy to an excipient in the branded product, that the compounded version solves. The agency concluded none of the GLP-1 nominations met this bar.

Many telehealth providers continued offering compounded semaglutide and tirzepatide through 503A pharmacies after the shortages ended, often by adding micronutrients like B12 or NAD to argue the product is a customized formulation rather than a straight copy of the branded drug. The May 1 proposed rule does not directly close this route. It targets 503B outsourcing supply. But the FDA has signaled increasing scrutiny of customized-formulation arguments, and the proposed rule should be read as part of a broader effort to wind down compounded GLP-1 access. See our guide on the FDA GLP-1 compounding crackdown for the enforcement context.

Proposed rules are not automatic. The FDA reviews comments and can revise the rule, withdraw it, or finalize it as written. The compounding industry, several telehealth companies, and patient advocacy groups will submit detailed comments arguing for clinical need based on cost-driven access barriers and the role of compounded GLP-1s in expanding obesity treatment to underinsured populations. However, the FDA has been consistent for two years that cost-driven access is not clinical need, so a substantive revision is unlikely. Finalization sometime in late 2026 or early 2027 is the most likely outcome.

If you are currently on compounded semaglutide or tirzepatide and the price difference versus branded is what is keeping you on therapy, start mapping a transition plan. Options include manufacturer savings programs (Wegovy and Zepbound both have direct-to-consumer cash pricing now), insurance appeal if your plan covers GLP-1s for obesity but is denying coverage, switching to a different mechanism if appropriate (oral semaglutide tablets are FDA-approved), or banking medication while compounded supply remains available. Do not stockpile beyond a reasonable supply since potency degrades over months of refrigerated storage.

Retatrutide is not FDA-approved. There is no shortage to invoke and no bulks list pathway for unapproved drugs. The May 1 proposed rule does not address retatrutide directly because retatrutide is not an approved drug whose bulk active ingredient is nominated for the list. Compounded retatrutide circulating in 2025 and 2026 has been operating in a different legal gray zone. See our retatrutide TRIUMPH-1 newsjack for context on where retatrutide stands in the approval pipeline.

Go to regulations.gov and search for FDA-2026-N or the specific Federal Register notice number 2026-08552. Click "Comment" on the docket and submit through the web form or as a PDF upload. Effective comments are specific, cite evidence, and address the FDA criteria for clinical need rather than just expressing opposition. Generic "do not ban compounded GLP-1s" comments carry less weight than detailed clinical case studies or economic analyses tied to the agency framework.

Related guides